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Abstract
Background—Studies have examined the association between acetaminophen (APAP) use and
asthma; however, their interpretation is limited by a number of methodological issues.
Objective—We sought to investigate the association between recent and chronic prescription
acquired acetaminophen use and asthma.
Methods—This was a retrospective case control study using a 10% random sample of the IMS
LifeLink commercial claims data from 1997 to 2009. Cases had to have at least 1 incident claim of
asthma. 3:1 controls matched on age, gender, and region were randomly chosen. APAP exposure,
dose and duration were measured in the 7 and 30 days (recent) and in the 1-year (chronic) look-
back period. Multivariable conditional logistic regression was used to estimate the risk of asthma
associated with acetaminophen use adjusted for comorbidities, other drugs increasing asthma risk,
and health system factors.
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Results—There were 28,892 cases and 86,676 controls with mean age 42.7 years and 37.7%
were males. 22.6% cases and 18.2% controls had APAP exposure in the pre-index year with mean
cumulative doses of 78.7 gm and 59.8 gm respectively. There was no significant association
between recent prescription APAP exposure and asthma (7 days: OR = 1.02, p = 0.74; 30 days:
OR = 0.97, p = 0.38). Cumulative prescription APAP dose in the year prior increased asthma risk
compared to APAP nonusers (<=1 kg: OR = 1.09, p <0.001 and >1 kg: OR = 1.60, p=0.02).
Duration of prescription APAP use >30 days was associated with elevated asthma risk (OR = 1.39,
p <0.001).
Conclusion—Chronic prescription-acquired APAP use was associated with an increased risk of
asthma while recent use was not. However, over the counter APAP use was not captured in this
study and further epidemiologic research with complete APAP exposure ascertainment and
research on pathophysiological mechanisms is needed to confirm these relationships.
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Introduction
Acetaminophen (APAP) is a widely used analgesic and antipyretic drug in the U.S. with
annual sales around $1 billion.1 Although considered relatively safe, concerns are being
expressed over excessive APAP consumption. The organs principally affected by APAP
overdose are the liver and kidneys, but dose-dependent lung toxicity may also occur.2
Instances of acute lung injury in patients with APAP-induced fulminant hepatic failure have
been reported previously.3 Advanced liver disease itself is associated with hypoxemia and
respiratory failure by various mechanisms4 suggesting that the lung injury may be a result of
physiological changes related to hepatic dysfunction rather than the direct effect of APAP.
Although the exact cause of lung injury among APAP-induced fulminant liver failure cases
is not clear, possible reasons cited are excessive production or lack of clearance of an
endogenous vasodilator associated with acute liver failure, increased intracranial pressure or
a direct cytotoxic effect of APAP metabolites on the lung.3 It has also been suggested that
APAP-induced glutathione depletion, independent of advanced liver disease, leads to lung
damage and regular APAP users without liver manifestations may be at an increased risk of
asthma.5 A review of publications on this topic2 reports an association between APAP use
and the development of asthma symptoms, but mechanistic studies in humans to support
these associations have not been performed. Alterations in lung glutathione levels6 and/or
metabolic activation of acetaminophen7, or cyclo-oxygenase mediated effects2 may
represent important mechanisms in the pathogenesis of asthma based on data from
experimental animal models.
The hypothesis of an association between APAP use and asthma was first proposed about a
decade ago.8 At the population level, associations between per capita APAP consumption
and the prevalence of asthma have been reported.8 The prevalence of asthma in the U.S. has
increased over the last thirty years for reasons not completely understood.2 Due to a surge in
asthma prevalence that occurred concurrently with increasing APAP use, there is renewed
interest about the role of acetaminophen in the development of asthma.2;8
Several reviews on this topic suggest a positive link between acetaminophen use and the risk
of asthma in adults and children9–11, but whether this association is causal or not remains
debatable.12 The interpretation of epidemiological studies 7;13–15 supporting the APAP-
asthma association in adults is limited by a number of issues like lack of rigorous case
definitions and not controlling for key confounders.2 Moreover, these studies have measured
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APAP use in terms of ‘frequency of use’ rather than the dose which plays a major role in
determining the degree of glutathione depletion. Finally, except for one study13, others have
used prevalent asthma cases instead of incident cases and there is no way of knowing if
APAP use preceded asthma or vice versa. According to our knowledge there are no large
scale claims based studies examining the association between APAP use and asthma. One of
the reasons could be incomplete APAP-exposure ascertainment due to incomplete recording
of over the counter (OTC) APAP use. Chronic prescription-acquired APAP use has
increased in the past few years, which parallels increases in the use of APAP-opioid
combination products.16;17 Our previous claims-based study of annual APAP use reported
approximately 30% of acetaminophen users with potential peak APAP consumption more
than the maximum recommended daily dose (4 grams per day) based exclusively on
prescription claims indicating that administrative claims data do capture high risk APAP
use.16 Unlike retrospective interview based studies, claims based studies are not biased due
to differential exposure recall of the cases compared to the controls. Pharmacy claims record
the start and end dates of a prescription and the amount of drug prescribed and, therefore,
are not biased by knowledge about the study outcome.18 Given these advantages and a lack
of claims based studies examining the APAP-asthma link, we sought to investigate the
association between recent and chronic prescription-acquired acetaminophen consumption
and asthma using a large nationally representative commercial claims database.
Methods
Study design and data source
This study was part of a larger project examining the association between recent and chronic
acetaminophen-use and hepatic (hepatotoxicity) and non-hepatic outcomes (renal disease
and asthma) using a retrospective case-control study design.19 The data source used was a
10% random sample of the IMS LifeLink Health Plans commercial claims data from 1997–
2009. This dataset consists of claims from over 98 managed care organizations in the U.S.
and is representative of the commercially insured population in the U.S. with respect to age,
gender, and region. The data includes pharmacy claims, inpatient and outpatient claims and
enrollment information for about 6 million individuals. The data contains records for both
OTC and prescription APAP containing products billed as a prescription claim. The APAP
records from this data source have been used in our previous study examining the trends in
acetaminophen use and potential overuse.16
Cases
Eligible cases were individuals >=18 years of age with at least one incident primary
diagnosis of asthma (493.xx)20 between January 1st 1998 to December 31st 2009. The date
of an incident asthma diagnosis was designated as the index date and the cases were required
to have continuous plan enrollment in the pre-index year. Since this study was part of a
larger project with 3 outcomes, to keep the methods consistent, cases with diagnoses of
hepatotoxicity, renal disease or asthma in the pre-index year were excluded. The exclusion
codes contained a broader set of related conditions in addition to the case definitions
(Appendix 1, 2, 3) to exclude persons with possible manifestations of the disease. We also
excluded cases with previous liver, kidney or lung transplant, those on immunosuppressant
therapy or those with liver, renal, respiratory-tract cancer or secondary malignancies.
Controls
Three controls for every case matched on age, gender and geographic location were
randomly selected from a group of individuals without evidence of asthma, hepatotoxicity
and nephrotoxicity at the end of the follow up period. Controls were assigned an index date
the same as the corresponding case and were required to have continuous plan enrollment in
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the pre-index year. We excluded controls that had a previous diagnosis code of
acetaminophen poisoning (965.4x).21 Other exclusion criteria were same as that of the cases.
Selection of cases and controls is depicted in Figure 1.
Acetaminophen exposure measures
APAP containing products were identified using unique Generic Product Identifier (GPI
codes) in the data. We measured any APAP exposure, doses and use durations for recent (7
and 30 days pre-index) and chronic (365 days pre-index) look-back periods. Doses
calculated were as follows:
1. Potential maximum daily dose (PMDD) in the 7 and 30 days pre-index: The highest
potential APAP dose calculated in the pre-index period using the days-supplied,
strength, and quantity fields in the data. Overlapping prescriptions were identified
using fill dates and days-supplied and the daily doses were summed to obtain the
potential maximum dose.
2. Potential average daily dose (PADD) in the pre-index month: Dose obtained by
summing the APAP doses contained in all prescriptions in the 30 days pre-index
divided by the total days of APAP use.
3. Cumulative dose in the pre-index year: The sum of APAP doses from all
acetaminophen-containing prescriptions during the pre-index year.
Table 1 describes the details of all the APAP use measures.
Other covariates
We obtained data on the following potential confounders in the pre-index period:
• Medical conditions: These were measured in the 365 days pre-index period for both
recent and chronic analyses and included eczema22, rhinitis23;24, chronic
obstructive pulmonary disease23, acute respiratory tract infections25;26,
gastrointestinal reflux disease27;28 and cancer 29 (Appendix 4).
• Drug variables: Drug exposure was measured in the 30 days pre-index for ‘recent
use’ analyses and in the 365 days pre-index for the chronic APAP use models. Use
of beta blockers25, antibiotics30 and non-steroidal anti-inflammatory drugs31 was
measured. We also controlled for use of single-ingredient unmixed opioid-
analgesics since their use is linked to respiratory depression.32
• Health System Variables: Using the enrollment information we obtained data on
insurance payer/plan type (Table 2) for our sample.
In addition to the above covariates, we also included a binary term for APAP use in the 30
days pre-index to control for recent use of APAP for the chronic APAP use models. We
could not adjust for race since it was not available in our data source.
Analysis
We obtained the baseline descriptive characteristics of our sample in the recent and chronic
pre-index periods. Chi-square tests were used to conduct bivariate comparisons between the
characteristics of cases and controls. Adjusted and unadjusted conditional logistic regression
models were used to determine the effect of recent and chronic APAP use on the risk of
asthma. Odds ratios (OR) and 95% confidence interval estimates obtained from the
regression are reported. Dose response relationships were assessed using the Cochran-
Armitage trend test. All analyses were carried out using SAS version 9.2 (SAS Institute,
Cary, North Carolina). This study was approved by the Institutional review board of the
University of Arkansas for Medical Sciences.
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28,892 incident asthma cases and 86,676 controls were included in the study (Figure 1). The
mean age of the sample was 42.8 years and 37.7% were males. Use of drugs and presence of
comorbidities that increase asthma risk was significantly higher among the cases compared
to the controls (Table 2). 1415 cases (4.9%) and 3271 controls (3.8%) were exposed to
acetaminophen for at least one day in the 30 days pre-index with mean maximum daily
doses of 3,393.5 mg and 3,346.4 mg respectively (Table 3). 6,537 cases (22.6%) and 15,809
controls (18.2%) had APAP exposure in the pre-index year with mean cumulative doses of
78.7 gm and 59.8 gm respectively. The mean total days of APAP use was significantly
greater among the cases (32.2 days) compared to the controls (24.7 days). More than 90% of
the prescriptions used by both cases and controls were for opioid/APAP combinations
(Table 3).
There was no significant association between any of the adjusted recent APAP exposure
measures and asthma (Table 4). To determine whether our study was sufficiently powered to
detect significant differences between cases and controls, we performed power analysis
using the Epicalc package in R software.33 Assuming a true odds ratio of 1.5, the power of
our study was >80% to detect significant differences with all the recent APAP variables
(data not shown).
Cumulative APAP dose in the pre-index year increased the risk of asthma by 10 – 60%
compared to APAP non-users (<=1 kg: OR=1.09, 95% CI=1.05 – 1.13 and >1kg: OR=1.60,
95% CI=1.09 – 2.37 respectively; Table 5). Doses >1kg conferred a significantly higher risk
compared to lower cumulative doses (p for trend =0.05). The risk of asthma with APAP use
<= 30 days in the pre-index year was 1.07 times that of non-users and increased to 1.39-fold
when APAP use duration was > 30 days (OR=1.07, 95% CI=1.03 – 1.11 and OR=1.39, 95%
CI=1.27 – 1.53 respectively; p for trend <0.001; Table 5). Categories of PMDD and total
APAP use duration in the pre-index year indicate that irrespective of the dose, the risk of
asthma with APAP use for <= 30 days was significantly lower than the risk conferred by
durations >30 days (Table 5).
Discussion
In our sample, recent prescription acquired APAP use did not increase the risk of asthma.
This is in agreement with studies reporting no-significant asthma risk with infrequent (<
monthly) APAP use or use for up to 22 days in a month.13;14 Although there are no studies
reporting an association between recent APAP use and asthma, acute APAP overdose may
have a direct cytotoxic effect on pneumocytes and lead to lung injury.3 Whether or not this
lung injury leads to the development of asthma requires further investigation. Chronic
prescription-acquired APAP use, however, increased the risk of asthma by 10 – 60%
compared to APAP non-users. This is consistent with a recent meta-analysis that reported a
74% increased asthma risk (a pooled OR of 1.74) among adult acetaminophen users
compared to non-users.34 The risk conferred by cumulative dose in the pre-index year
increased in a dose-dependent fashion. This is in keeping with the theory that APAP-
induced glutathione depletion in the lungs is dose-dependent.2 Consistent with the existing
epidemiologic literature13;14, asthma risk also increased with APAP use duration.
Our results are biologically plausible based on pathophysiological mechanisms describing
APAP-induced lung toxicity. The primary organs affected by APAP overdose are the liver
and the kidneys. However, APAP also depletes glutathione in the lung tissue which leads to
contraction of the airway smooth muscles by reactive oxygen species resulting in
inflammation and bronchoconstriction.2;13;14 This could lead to symptoms of asthma in
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individuals who otherwise have sub-clinical disease.14 Other mechanisms of APAP-induced
lung injury are through the lack of inhibition of the cycloxygenase enzyme and through
increased IgE antibody levels as a result of antigenic activity of acetaminophen.34
According to our knowledge, there is a paucity of research about the detailed mechanisms of
APAP-induced lung injury, particularly about the time of onset of lung injury after APAP
consumption in humans. If it is true that APAP first affects the liver and kidneys before
affecting the lungs, the process of lung-injury might be slower and could require prolonged
consumption of acetaminophen. It has been reported that cross-sensitivity to acetaminophen
may go unrecognized in aspirin-sensitive asthmatics since the effect of acetaminophen on
the lungs is smaller and of slower onset than with aspirin.14 This finding, although in
asthmatic individuals, provides some evidence of the slow onset of lung injury with
acetaminophen. While an association between chronic APAP consumption and asthma is
consistent with other studies and biologically plausible based on the theory of glutathione
depletion, further pathophysiological research is warranted to confirm the slower onset of
APAP-induced lung toxicity.
Our results should be interpreted in light of exposure misclassification bias. We calculated
maximum daily doses based on days supply and quantity in our dataset and assumed that
overlapping prescriptions were consumed concurrently which could overstate the PMDD in
some instances and bias the results towards the null. This is why we refer to ‘potential’
maximum and average daily doses, however, PMDD was not significantly related to asthma
in our study and this calculation does not affect our other APAP dose measures. A larger
concern is not accounting for un-recorded over the counter (OTC) acetaminophen use that
could bias our results. The APAP product market consists of 48% prescription and 52%
OTC products35; so we may have accounted for approximately half of all APAP use with
our data and our calculated APAP use measures may perhaps be understated substantially. If
the misclassification is non-differential, ie., an equal proportion of cases and controls are
misclassified, our results would most likely be biased towards the null. If a greater
proportion of cases which exhibited higher comorbidity levels than controls use unrecorded
APAP, they could be differentially misclassified as non-exposed and the results would also
bias our results towards the ‘null’. While this could be a reason for the lack of an association
between recent APAP use and asthma, the same consideration makes our observed
association between chronic-APAP use and asthma more plausible; perhaps the strength of
association understated. The role of confounding by indication (in this case, reverse
causality bias) should be considered to explain the positive association observed in our
study.36 This could arise if a greater proportion of cases than controls used APAP products
in the pre-index period to manage early manifestations of asthma. However, 93.5% of all
APAP prescriptions of cases were opioid-APAP combinations primarily used for pain while
cough-cold prescriptions, which would generally be used to treat asthma like symptoms,
accounted for less than 1% of APAP use and cough-cold APAP product use was slightly
higher in controls compared to cases. Hence bias due to reverse causality is unlikely to be a
significant concern.
Opioid analgesics have been linked to respiratory depression.32 Since an overwhelming
majority of the APAP prescriptions in our sample were for opioid-APAP combinations, the
possibility of opioids contributing to the development of asthma should be considered.
Respiratory depression is a greater problem with the use of single ingredient unmixed
opioids compared to opioid-combinations37 which is likely due to a higher narcotic-dose in
un-mixed opioids. 1.9% of the cases and 1.4% of controls used un-mixed opioids in the pre-
index year and in spite of controlling for this, we observed a positive association between
chronic APAP use and asthma. The models without this adjustment provided similar results.
Respiratory depression is kept to a minimum in chronic pain patients maintained on
regularly monitored opioid doses32 suggesting that respiratory depression may not be a
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significant concern with regular long-term opioid use. A consensus statement from the
American Academy of Pain Medicine and American Pain Society states that opioid induced
respiratory depression is a short lived phenomenon and generally occurs in opioid-naïve
patients than patients on chronic opioid therapy.38 This could be because patients develop
tolerance to the opioid respiratory-depressant effect over time.39 Therefore, respiratory
depression is rare among patients on chronic opioid therapy39 and this would support the
notion that it is APAP and not the opioids in these combination products that are associated
with asthma in our chronic use models.
Given the increased odds of asthma with chronic APAP consumption, clinical decisions
guiding APAP use should be based on a thorough risk-benefit assessment of APAP. A
clinical trial reports the use of 4gm/day of APAP for 12 months to be safe and effective in
287 osteoarthritis patients.40 However, this trial did not measure lung-disorders as one of
their outcomes and there is no way of knowing if lung function was affected with APAP use
for a year. Adequately powered clinical trials measuring lung function with chronic APAP
use are needed to more clearly elucidate the asthma risks of chronic APAP to aid its risk-
benefit assessment. Common alternatives to APAP may be non-steroidal anti-inflammatory
drugs and opioid analgesics. However, these are associated with a number of adverse
events41–43 and a thorough comparison of risk-benefit profile of APAP and other analgesic
alternatives should be used to guide clinical and policy recommendations about APAP use.
Our results should be interpreted in light of some other limitations in addition to exposure
misclassification. First, since our data source did not include clinical measures to detect
asthma, we used ICD-9-CM codes exclusively to define asthma cases. The ICD-9-CM codes
for asthma have a low sensitivity and we may not have captured all true cases which
increases the possibility that some controls may indeed have asthma.44 Since we selected
controls from amongst the ‘asthma free’ individuals at the end of the follow up period, the
ORs calculated in the study represent the odds ratios in the base population and not the risk/
rate ratio.45 Second, in the absence of a well established definition of ‘chronicity’ of APAP
use, we used a somewhat arbitrary time-window of 1 year. Third, our study only included
the subjects >= 18 years of age. The incidence of asthma is greater in pediatrics compared to
adults, and if acetaminophen was the preferred analgesic in individuals with a previous
history of asthma (since other analgesics like NSAIDS exacerbate asthma) the results could
be biased away from the null due to confounding by indication. Finally, since this was an
insurance database, we did not have data on factors like body-mass index and environmental
exposure to allergens and anthropometric measures, and therefore the possibility of omitted
variable bias cannot be excluded.
Conclusion
Consistent with other studies, chronic prescription-acquired acetaminophen use was
significantly associated with asthma in a dose-dependent manner while recent use was not.
Based on our study, it does not appear that occasional short term use of prescription APAP
confers additional asthma risk, but long term chronic use should be more carefully
considered, particularly in asthma prone individuals. It would be premature to recommend
avoidance of APAP, particularly in those with symptoms of asthma because the most
common substitute analgesics, NSAIDS, have been linked to asthma. Epidemiologic studies
with more complete APAP use measures, including OTC and prescription acquired use, are
warranted to confirm our findings in addition to more basic research to determine the time of
onset of lung injury and the causal pathways of asthma associated with APAP use.
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Appendix 1–ICD-9-CM Codes for Asthma and related conditions
Table 1.1




493.2x Chronic obstructive asthma
493.8x Other forms of asthma
493.9x Asthma, unspecified
Table 1.2
ICD-9 codes for exclusions of asthma cases 1 year before the index date (used along with
table 1.1)
Code Description
786.05 Shortness of breath
786.07 Wheezing
786.2x Cough
786.09 Other respiratory distress, insufficiency
162 Malignant neoplasm of trachea, bronchus,
and lung
209.21 malignant carcinoid tumor of bronchus
231.2 Carcinoma in situ of respiratory system:Bronchus and lung
V10.11 Personal history of malignantneoplasm: Bronchus and lung
996.84 Complications of transplanted organ:Lung
V426
Organ or tissue replaced by transplant:
Lung
32850, 32851,
32852, 32854 Lung transplant CPT codes
Appendix 2–ICD-9-CM Codes for Hepatotoxicity and related conditions
Code Description
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286.7 Acquired coagulation factordeficiency
571.xx Chronic liver disease and cirrhosis
572.xx Liver abscess and sequelae ofchronic liver disease
573.xx Other disorders of liver
070.0–070.9 Viral hepatitis
277.3 Amyloidosis
751.62 Congenital cystic disease ofliver
271.0 Glycogen infiltration of liver
789.1 Hepatomegaly not otherwisespecified
452 Portal vein thrombosis
095.3 Syphilis of liver
091.62 Secondary syphilitic hepatitis
130.5 Hepatitis due to toxoplasmosis
155.xx Neoplasm of the liver andintrahepatic bile ducts
782.4 Jaundice, unspecified, not ofnewborn
996.82 Complications of transplantedorgan: Liver
V427 Organ or tissue replaced bytransplant: Liver
47125, 47130, 47135,,
47140-42 Liver transplant CPT codes





583.xx Nephritis and nephropathy, not specifiedas acute or chronic
584.xx Acute kidney failure
585.xx CHRONIC RENAL FAILURE
586 Renal failure, unspecified
587 Renal sclerosis, unspecified
588.xx Disorders resulting from impaired renalfunction
589.xx Small kidney of unknown cause
591 HYDRONEPHROSIS
593.xx Other disorders of kidney and ureter
596.xx Other disorders of bladder
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600.xx Hyperplasia of prostate
753.1x Cystic kidney disease
189.0 189.1 209.24,
V1052, V1053
Cancer of the kidney and renal pelvis
996.81 Complications of transplanted organ:
kidney








Kidney transplant CPT codes
Appendix 4–ICD-9-CM codes of medical conditions used as covariates for
asthma











491.xx, 492.xx, 494.xx, 496.xx
Allergic rhinitis 477.xx
Esophageal reflux 530.81
Cancer Based on AHRQ Clinical Classification Software
Designation
( Cancer codes from cluster 2, http://www.hcup-us.ahrq.gov/toolssoftware/ccs/
AppendixCMultiDX.txt)
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Table 1





Recent APAP exposure measures : measured in the 7 days pre-index
APAP exposure in
the 7 day pre-index
period
Use of an APAP containing
prescription for at least one day in








in the 7 day pre-
index period
The highest potential APAP dose on
any day during the 7 days pre-index.
Calculated using the days-supplied,
strength, and quantity fields in the
data. Overlapping prescriptions
were identified using fill-dates and
days-supplied and the daily doses






Recent APAP exposure measures : measured in the 30 days pre-index
APAP exposure in
the 30 days pre-
index period
Use of an APAP containing
prescription for at least one day in








in the 30 days pre-
Index
The highest potential APAP dose on
any day during the 30 days pre-
index. Calculated using the days-
supplied, strength, and quantity
fields in the data. Overlapping
prescriptions were identified using
fill-dates and days-supplied and the











Dose obtained by summing up the
APAP doses contained in all
prescriptions in the 30 days pre-
index and dividing by the total days







Chronic APAP exposure measures : measured in the pre-index year
Cumulative dose
(CD) for one year
pre-index
Sum of APAP doses in all APAP









Total number of days of APAP use
in the pre-index year
1 to 30 days






Joint effect of APAP dose and
duration of APAP use in the pre-
index year
PMDD <= 4gm/day &
duration <= 30 days
PMDD <= 4gm/day &
duration > 30 days
PMDD > 4gm/day & duration
<= 30 days







APAP : Acetaminophen; CD: Cumulative dose; PADD: Potential average daily dose; PMDD: potential maximum daily dose
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Table 2
Demographic, Comorbidity and Drug Exposure Variables for Asthma Cases and Matched Controls :
Pharmetrics Claims Data 1997–2009
Variable Cases Controls
N = 28,892 N = 86,676
Demographic variables
Age (Mean, SD)
Age at index date (years) 42.77 15.1 42.77 15.1
Gender (n,%)
male 10878 37.7% 32634 37.7%
Region (n,%)
East 6717 23.3% 20151 23.3%
West 4125 14.3% 12375 14.3%
Mid West 11207 38.8% 33621 38.8%
South 6843 23.7% 20529 23.7%
Health system variables (n,%)
Medicaid 927 3.2% 1598 1.8%
Commercial HMO 7791 27.0% 24280 28.0%
Medicare 942 3.3% 2402 2.8%
non-HMO commercial and unknown type 19232 66.6% 58396 67.4%
Pre-index exposure to drugs that increase the risk of asthma (n,%)
Antibiotic exposure - 30 days 4327 15.0% 6091 7.0%
Antibiotic exposure - 365 days 14325 49.6% 32227 37.2%
NSAID exposure - 30 days 942 3.3% 1920 2.2%
NSAID exposure - 365 days 5094 17.6% 12004 13.9%
Beta blocker exposure - 30 days 1432 5.0% 3992 4.6%
Beta blocker exposure - 365 days 1906 6.6% 5256 6.1%
Use of unmixed-opioids – 365 days 565 1.9% 1247 1.4%
Comorbidity variables in the 365 days pre-index (n,%)
Eczema 1640 5.7% 3614 4.2%
Respiratory tract infection 10424 36.1% 14712 17.0%
Rhinitis 5307 18.4% 5091 5.9%
COPD 1546 5.4% 1042 1.2%
GERD 1674 5.8% 3151 3.6%
Cancer 2003 6.9% 5557 6.4%
COPD : Chronic obstructive pulmonary disease ; GERD: Gastro-esophageal reflux disease; NSAID: Non-steroidal anti-inflammatory drugs.
p-values for all variables < 0.05
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Table 3
Prescription Acquired Acetaminophen Exposure, Doses and Durations of Use for Asthma Cases and Matched
Controls in the Pre-Index Period
Variable Cases Controls
N = 28,892 N = 86,676
Acetaminophen exposure variables
APAP exposure for at least one day - 7 days (n,%) 798 2.8% 1721 2.0%
APAP exposure for at least one day - 30 days (n,%) 1415 4.9% 3271 3.8%
APAP exposure for at least one day – 365 days (n,%) 6537 22.6% 15809 18.2%
Maximum daily dose in the 7 days pre-index
MDD (mg) - 7 days (Mean a, SD) 3004.4 4871.3 2947.2 7533.1
MDD (<= 4gm/day) - 7 days (n,%) 690 2.4% 1486 1.7%
MDD (> 4gm/day) - 7 days (n,%) 108 0.4% 235 0.3%
Maximum daily dose in the 30 days pre-index
MDD (mg) - 30 days (Mean b†, SD) 3393.5 5219.0 3346.4 6279.2
MDD (<= 4gm/day) - 30 days (n,%) 1148 4.0% 2632 3.0%
MDD (> 4gm/day) - 30 days (n,%) 267 0.9% 639 0.7%
Average daily dose in the 30 days pre-index
ADD (mg) - 30 days (Mean b, SD) 2940 4133.0 2946.4 4374.0
ADD (<= 4gm/day) - 30 days (n,%) 1240 4.3% 2819 3.3%
ADD (> 4gm/day) - 30 days (n,%) 35 0.6% 45 0.5%
Cumulative dose in the pre-index year
Cumulative dose (gm) in the pre-index year (Mean b,SD) 78.7 224.6 59.8 157.1
Cumulative dose (<= 1kg) (n,%) 6488 22.5% 15734 18.2%
Cumulative dose (> 1kg) (n,%) 49 0.2% 75 0.1%
Duration of APAP use in the pre-index year
Total days of APAP use (Mean c,SD) 32.2 67.9 24.7 57.6
Total days of APAP use (<= 30 days) (n,%) 5309 18.4% 13559 15.6%
Total days of APAP use (> 30 days) (n,%) 1228 4.3% 2250 2.6%
PMDD and Duration of APAP use in the pre-index year
PMDD <= 4gm and total days <= 30 days (n,%) 4002 13.9% 10294 11.9%
PMDD <= 4gm and total days > 30 days (n,%) 654 2.3% 1161 1.3%
PMDD > 4gm and total days <= 30 days (n,%) 1307 4.5% 3265 3.8%
PMDD > 4gm and total days > 30 days (n,%) 574 2.0% 1089 1.3%
Types of APAP prescriptions for 22,346 APAP users
Opioid/APAP combinations 19740 93.5% 39480 92.5%
Cough-cold products 10 0.1% 72 0.2%
Non-opioid combination analgesics 1260 6.0% 2924 6.9%
APAP only d 97 0.5% 226 0.5%
ADD : Average daily dose; APAP : Acetaminophen; MDD : Maximum daily dose
a
mean values calculated for 798 cases and 1721 controls
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b
mean values calculated for 1415 cases and 3271 controls
b
||,¶ mean values calculated for 6537 cases and 15809 controls
d
not significant at alpha = 0.05
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Table 5















Cumulative dose in the pre-index year
<= 1kg a 6488 15734 1.31 (1.26 – 1.35) 1.09 (1.05 – 1.13) <.001
> 1kg a 49 75 2.08 (1.45 – 2.98) 1.60 (1.09 – 2.37) 0.02
APAP use 30days
preindex
1415 3271 - 0.96 (0.89 – 1.03) 0.24
Total APAP use duration in the pre-index year
<= 30days b 5309 13559 1.24 (1.20 – 1.28) 1.07 (1.03 – 1.11) 0.01
> 30days b 1228 2250 1.74 (1.62 – 1.87) 1.39 (1.27 – 1.53) <.001
APAP use 30days
preindex
1415 3271 - 0.87 (0.80 – 0.95) 0.01
Categories of PMDD in the pre-index year and the total days of APAP use
PMDD <= 4gm and total
days <= 30 days c
4002 10294 1.23 (1.18 – 1.28) 1.06 (1.02 – 1.11) 0.01
PMDD <= 4gm and total
days > 30 days c
654 1161 1.79 (1.63 – 1.98) 1.44 (1.29 – 1.61) <.001
PMDD > 4gm and total
days <= 30 days c
1307 3265 1.27 (1.19 – 1.36) 1.09 (1.01 – 1.17) 0.01
PMDD > 4gm and total
days > 30 days c
574 1089 1.68 (1.51 – 1.86) 1.34 (1.19 – 1.52) <.001
APAP use 30days
preindex
1415 3271 - 0.87 (0.80 – 0.95) 0.01
Reference Category: No APAP exposure
a
coefficients of the two categories were marginally different, p = 0.0521
b
p <0.001 for trend
c
Coefficients on categories I & II and categories III & IV were significantly different, p <0.0001 and p = 0.0020 respectively
d
Analyses adjusted for the following (1)Acute APAP exposure in the 30 days pre-index (2) drug exposure variables (365 days pre-index) –
antibiotics, non-steroidal anti-inflammatory drugs, beta blockers (3) diagnosis variables (365 days pre-index) - eczema, rhinitis, chronic obstructive
pulmonary disease, respiratory tract infections, gastrointestinal reflux disease, cancer and (4) health system variables (365 days pre-index) –
Medicare, Medicaid, Commercial health maintenance organization (5)use of unmixed opioids in the pre-index year
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